NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment

Not Yet RecruitingPhase 4

Sponsor: Hanyang University

Conditions: Mild Cognitive Impairment, Alzheimer's Disease

Interventions: Ginkgo Biloba Extract 240 mg, Placebo

This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.

Eligibility overview

Sex: ALL

Age: 20 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Age 20 years or older
* Clinical Dementia Rating (CDR) score of 0.5
* Patients clinically indicated for treatment with Ginkgo biloba extract

Exclusion Criteria:

* Current use of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine.
* Refusal to provide informed consent.
* Presence of neurological or psychiatric conditions other than Alzheimer's disease that may affect cognitive function.
* Known hypersensitivity to Ginkgo biloba extract or any of its components.
* Pregnant women.
* Genetic conditions associated with lactose intolerance, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
* Presence of bleeding disorders at screening, or requirement for continuous use of medications that may affect study drug efficacy (e.g., anticoagulants, antiplatelets, thrombolytics, peripheral vasodilators, PGE1 and its derivatives).
* Any condition that, in the opinion of the investigator or study staff, makes the participant unsuitable for the study or unable to comply with study procedures.